Abstract
Much evidence has accumulated implicating the p53 gene as of importance in breast carcinogenesis. However, much still remains to be uncovered on the specific downstream pathways influenced by this important activator/repressor of transcription. This study investigated the effects of a p53 null genotype on the transcriptome of ‘normal’ mouse mammary epithelium using a unique in vivo model of preneoplastic transformation. We used SAGE for the comparative analysis of p53 wild type (wt) and null mammary epithelium unexposed and exposed to hormonal stimulation. Analysis of the hormone exposed samples provided a comprehensive view of the dramatic changes in gene expression as consequence of the functional differentiation of the mammary epithelium in an in vivo system. We detected the dysregulation in p53null epithelium of <1% of the transcriptome. Changes in expression affected not only known p53 target genes, but also several unexpected genes such as Expi (Wdnm1), Cyp1b1, Gelsolin, Ramp2 and class I MHC genes. The dysregulation of specific genes and their potential use as preneoplastic markers was further validated using an independent model of premalignant mammary outgrowth lines. This is the first study to examine the transcriptome of very early stages of preneoplastic progression in an in vivo model that mimics human breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Asch HL, Head K, Dong Y, Natoli F, Winston JS, Connolly JL, Asch BB . 1996 Cancer Res. 56: 4841–4845
Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC, Aldaz CM . 2000 Cancer Res. 60: 5977–5983
Cui XS, Donehower LA . 2000 Oncogene 19: 5988–5996
Dear TN, Ramshaw IA, Kefford RF . 1988 Cancer Res. 48: 5203–5209
Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, Gray J, Bradley A, Medina D, Varmus HE . 1995 Genes Dev. 9: 882–895
Elledge RM, Allred DC . 1994 Breast Cancer Res. Treat. 32: 39–47
Goepfert TM, McCarthy M, Kittrell FS, Stephens C, Ullrich RL, Brinkley BR, Medina D . 2000 FASEB J. 14: 2221–2229
Griffioen M, Steegenga WT, Ouwerkerk IJ, Peltenburg LT, Jochemsen AG, Schrier PI . 1998 Mol. Immunol. 35: 829–835
Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, Butel JS, Medina D . 2000 Oncogene 19: 1052–1058
Klein B, Klein T, Figer A, Bleiberg M, Shapira J, Loven D, Livni E, Lurie H, Niska A . 1991 Cancer 67: 2295–2299
Kwiatkowski DJ . 1999 Curr. Opin. Cell Biol. 11: 103–108
Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marra MA, Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, Kinzler KW, Strausberg RL, Riggins GJ . 1999 Cancer Res. 59: 5403–5407
Levine AJ . 1997 Cell 88: 323–331
Li B, Murphy KL, Laucirica R, Kittrell F, Medina D, Rosen JM . 1998 Oncogene 16: 997–1007
McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM . 1998 Nature 393: 333–339
Medina D . 1996 J. Mammary Gland Biol. Neoplasia 1: 5–19
Medina D, Kittrell F . 2000 Methods in Mammary Gland Biology and Breast Cancer Research Ip MM and Asch BB (eds) NYC: Kluever Academic Press pp. 137–145
Medina D, Kittrell FS, Shepard A, Stephens LC, Jiang C, Lu J, McCarthy M, Ullrich RL . 2002 FASEB J., 16: 881–883
Morrison BW, Leder P . 1994 Oncogene 9: 3417–3426
Oehler MK, Norbury C, Hague S, Rees MC, Bicknell R . 2001 Oncogene 20: 2937–2945
Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B . 1997 Nature 389: 300–305
Robinson GW, McKnight RA, Smith GH, Hennighausen L . 1995 Development 121: 2079–2090
Velculescu E, Zhang L, Vogenstein B, Kinzler W . 1995 Science 270: 484–487
Williams JA, Phillips DH . 2000 Cancer Res. 60: 4667–4677
Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A, Asch BB . 2001 Breast Cancer Res. Treat. 65: 11–21
Zhang L, Zhou W, Velculescu V, Kern S, Hruban R, Hamilton S, Vogelstein B, Kinzler K . 1997 Science 276: 1268–1272
Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ . 2000 Genes Dev. 14: 981–993
Zhao Y, Hague S, Manek S, Zhang L, Bicknell R, Rees MC . 1998 Oncogene 16: 409–415
Acknowledgements
This work was supported by NIH Grant CA84243 and NIEHS Center Grant ES07784. We gratefully acknowledge Rebecca Deen for manuscript preparation and Joi Holcomb for preparation of artwork.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aldaz, C., Hu, Y., Daniel, R. et al. Serial analysis of gene expression in normal p53 null mammary epithelium. Oncogene 21, 6366–6376 (2002). https://doi.org/10.1038/sj.onc.1205816
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205816
Keywords
This article is cited by
-
Transcriptomic signature of Bexarotene (Rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models
BMC Medical Genomics (2008)
-
Wild-type p53 and p73 negatively regulate expression of proliferation related genes
Oncogene (2008)
-
cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model
Laboratory Investigation (2004)